Latest Daily News

Latest News

May 26, 2016

Drs. Rana R. McKay and Toni K. Choueiri discuss the ongoing studies exploring novel agents and combinations that will likely inform the future treatment landscape of patients with mRCC.

Read more
May 29, 2015

Dr. George J. Bosl will receive the ASCO Distinguished Achievement Award for his pioneering work in research and patient care dealing with the management of testicular cancer and other genitourinary cancers.

Read more
May 30, 2015

 Ovarian function suppression has the potential to affect fertility, however providers should be aware of the role of adjuvant therapy and other interventions in helping patients maintain bone density and reduce fracture risk.

Read more
May 31, 2015

ASCO published guidelines and endorsements addressing myriad aspects of prostate cancer care, including radiotherapy in men after prostatectomy, hormone therapy and chemotherapy, and survivorship care.

Read more

May 31, 2015

Learn more about the inaugural year of the Maintenance of Certification (MOC) Self-Assessment Activity at the 2015 Genitourinary Cancer Symposium through an interview with participant Dr. Elizabeth Guancial.

Read more
May 30, 2015

Arguments for treating men with castration-resistant prostate cancer early or late were provided based on data from CHAARTED and GETUG-AFU 15. In addition, the use and sequencing of Ra 223 were also provided based on analyses from ALSYMPCA and datasets from clinical practice.

Read more
June 7, 2015

Treatment with the Wee1 inhibitor AZD1775 plus carboplatin showed encouraging antitumor activity in patients with p53-mutated ovarian cancer that is refractory or resistant to standard first-line therapy.

Read more
May 31, 2015

The randomized phase III TOAD trial investigated whether immediate intervention with androgen deprivation therapy would improve overall survival compared with delayed androgen deprivation therapy in patients with prostate cancer.

Read more
May 30, 2015

The Education Session “Managing Ovarian Cancer in the Older Woman: How to Best Select and Sequence Surgery and Chemotherapy for Optimal Outcome” addresses the challenges clinicians face in treating older women with ovarian cancer.

Read more
May 31, 2015

The addition of docetaxel chemotherapy to standard therapies for men with either high-risk, localized prostate cancer (RTOG 0521, #LBA5002) or hormone-naive, advanced prostate cancer (STAMPEDE, #5001) resulted in significant OS improvements.   

Read more
May 31, 2015

The addition of bevacizumab to everolimus is associated with a significant improvement in efficacy but a high rate of toxicity in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (pNETs), according to results of the randomized, phase II CALGB 80701 trial.

Read more
May 31, 2015

The addition of erlotinib to gemcitabine adjuvant therapy provides no benefit in patients with R0-resected pancreatic cancer, suggest results of the randomized, open-label, phase III CONKO-005 trial.

Read more
May 31, 2015

One year of neratinib improved the rate of invasive disease-free survival compared to placebo in patients with HER2-positive early stage breast cancer who had undergone prior adjuvant therapy with chemotherapy and trastuzumab, according to results of a randomized phase III trial.

Read more